Virbac SA (France) Today
| VIRP Stock | EUR 324.00 0.50 0.15% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Virbac SA is trading at 324.00 as of the 26th of November 2024, a 0.15% up since the beginning of the trading day. The stock's open price was 323.5. Virbac SA has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Virbac SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Virbac SA produces and sells medicines and vaccines for companion and food-producing animals. Virbac SA was founded in 1968 and is headquartered in Carros, France. VIRBAC operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. The company has 8.44 M outstanding shares. More on Virbac SA
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Virbac Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Virbac SA's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Virbac SA or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers - Major, Healthcare (View all Sectors) |
Virbac SA (VIRP) is traded on Euronext Paris in France and employs 5,120 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.4 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Virbac SA's market, we take the total number of its shares issued and multiply it by Virbac SA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Virbac SA operates under Healthcare sector and is part of Drug Manufacturers - Major industry. The entity has 8.44 M outstanding shares.
Virbac SA has accumulated about 63.55 M in cash with 129.9 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.55.
Check Virbac SA Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Virbac SA is €2.4 Billion. Virbac SA maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with substantial debt, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company at some point.
Check Virbac Ownership Details
Virbac SA Risk Profiles
Although Virbac SA's alpha and beta are two of the key measurements used to evaluate Virbac SA's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.44 | |||
| Standard Deviation | 2.37 | |||
| Variance | 5.62 | |||
| Risk Adjusted Performance | (0.01) |
Virbac Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Virbac SA without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Virbac SA Corporate Management
Elected by the shareholders, the Virbac SA's board of directors comprises two types of representatives: Virbac SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Virbac. The board's role is to monitor Virbac SA's management team and ensure that shareholders' interests are well served. Virbac SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Virbac SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nathalie Pollet | Head Devel | Profile | |
| Marc Bistuer | Head CEO | Profile | |
| Sandrine Brunel | Head Communications | Profile | |
| Bertrand Havrileck | Biologicals RD | Profile | |
| Sebastien Huron | Chairman Board | Profile | |
| Habib Ramdani | Deputy CFO | Profile | |
| Manuela Rodrguez | Director Projects | Profile |
Other Information on Investing in Virbac Stock
Virbac SA financial ratios help investors to determine whether Virbac Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Virbac with respect to the benefits of owning Virbac SA security.